Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Name and title: Richard Leigh, executive vice president, general counsel and corporate secretary Age: 45 Combats cancer: Cell Therapeutics Inc. (CTI), a biopharmaceutical firm based in Seattle, is the developer of “an integrated portfolio” of oncology products with an emphasis on safer and more effective cancer therapies and less toxic treatments. CTI also acquires and commercializes innovative approaches to fighting the disease, which is the No. 1 killer of Americans younger than 85. Founded in 1991, CTI employs 401 (272 in the United States, the balance in its European division in suburban Milan, Italy) and reported 2004 revenues of $29.6 million. Its stated goal is “to make cancer into a treatable, chronic disease with therapies that impact survival without impacting the patients’ quality of life.” Finance specialist: One of Leigh’s primary duties is to participate in financing deals. He also negotiates research agreements. As corporate secretary, he spends “a considerable amount of time” on Sarbanes-Oxley responsibilities for his Nasdaq-listed company, characterizing the current corporate climate as “a challenging, but very exciting time” to be a board member of a public company. CTI also appears on the Italian stock exchange, necessitating for Leigh familiarity with Italian laws and listing requirements. The Italian law firm Gianni, Origoni, Grippo & Partners, which also has a New York office, assists in such matters. Leigh also ensures that the necessary forms of insurance are in place, including D&O policies for directors and officers. Leigh serves as counsel to CTI’s board of directors and works with committee chairmen, particularly those of the audit and governance committees. He has input with the company’s interdisciplinary and interdepartmental research teams, including groups focusing on regulatory affairs, quality assurance and clinical development. Most pertinent regulations are under the aegis of the U.S. Food and Drug Administration (FDA), with some involving the National Institutes of Health. Leigh said that the Vioxx situation, in which Merck & Co. withdrew its arthritis medication from the market following claims that Vioxx caused health problems, has “impacted all pharmaceutical companies and biopharmaceutical companies. Everybody is watching very carefully what is going on in the industry vis-�-vis the FDA.” Leigh also oversees litigation and said that there is nothing timely that he can discuss, although he alluded to a recent shareholders’ class action filed against CTI, “which we are analyzing and plan to vigorously defend.” life sciences and leigh: His is a “very transactional-oriented field,” exemplified by Cell Therapeutics’ merger with its Italian counterpart, now subsidiary, Novuspharma SpA. Although the deal predated his arrival, Leigh has been active in the postmerger integration phase of the companies, crucial to the expansion of CTI’s patient pool for clinical trials and enlargement of its customer base in the process. The company’s commercial products include cutting-edge treatments for leukemia and other blood-related cancers, and Xyotax, used to combat lung and ovarian cancers. The latter features proprietary technology to allow the drug to remain inactive while traveling through the bloodstream to the tumor, thus minimizing side effects. Leigh, along with CTI’s patent specialists, is immersed in intellectual property. They manage IP assets to ensure that CTI’s future commercial intentions have exclusivity, and seek to avoid potential liability by reviewing third-party exclusivities. Attending biopharmaceutical and legal conferences, and reading MedAd News, help Leigh to keep current in his fluid field. Legal team: Cell Therapeutics’ legal arm consists of Leigh and four other attorneys who focus on corporate affairs and patents. A senior patent paralegal, a contract administrator and two other administrators provide key support. Leigh is also responsible for corporate security and risk management personnel, representing another six positions. “Historically,” Leigh said, “we have done a fair amount of outside work,” but in trying to buck that trend, the team has currently achieved a 50/50 split. Outside firms relied upon include the San Francisco office of Palo Alto, Calif.-based Wilson Sonsini Goodrich & Rosati; the Seattle and Washington offices of Heller Ehrman White & McAuliffe; and the San Francisco office of O’Melveny & Myers. Foley & Lardner gets the call for specialized patent and intellectual property cases, and various firms are retained by Leigh on a case-by-case basis to handle litigation and regulatory matters. He reports to President and Chief Executive Officer James A. Bianco, CTI’s principal founder. Route to the top: Leigh graduated from Brown University in 1981 and Columbia Law School in 1986. He also achieved a master’s degree in international relations from Washington’s Johns Hopkins School of International Studies. His law career began with eight years at the Seattle office of Foster Pepper & Shefelman where, as a corporate lawyer, he was involved in financing arenas for the Portland Trail Blazers and Miami Heat of the National Basketball Association. In 1997 he became the first vice president and general counsel of pro football’s Seattle Seahawks, engaging in players’ and coaches’ contracts, employee grievances and other personnel and administrative matters. Next, he managed the legal department at Vulcan Inc., the Seahawks’ parent company owned by Microsoft Corp. co-founder Paul G. Allen. Bringing a major construction project for the Seahawks’ new stadium to fruition, while defying doubters over a four- to five-year period, is a career highlight from his days at Vulcan. CTI then beckoned, and in August 2004, Leigh was hired in his current roles. He has also served with the Seattle Seahawks Charitable Foundation, the Greater Seattle Chamber of Commerce and the Kingdome Renovation Task Force, among other community-based activities. Personal: Leigh, a native of Los Angeles, is married to Desir�e Blackwell Leigh. He savors long walks on the beach with their son Trey, age 9. Last books and movie: The Bonus Army: An American Epic, by Paul Dickson and Thomas B. Allen; The Barefoot Book of Father and Son Tales, by Josephine Evetts-Sacker; and Sideways.

This content has been archived. It is available exclusively through our partner LexisNexis®.

To view this content, please continue to Lexis Advance®.

Not a Lexis Advance® Subscriber? Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via Lexis Advance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at [email protected]


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2020 ALM Media Properties, LLC. All Rights Reserved.